PREHISTIN™ IS PATENTED

In 1992, Cobalis acquired the US patent for the use of cyanocobalamin as an effective method of reducing immunoglobulin (IgE) levels in humans. The Company also, in 2001, received patent approval for using cyanocobalamin for the treatment of allergic disease (allergies, asthma, etc.), via a wide variety of delivery mechanisms. The patents on PreHistin™ describe research which demonstrated reductions in allergy symptoms such as sneezing, nasal congestion and runny nose.

Patents

Cobalis’ US Patent #6,255,294 covers patient-friendly ways to treat IgE-mediated allergic diseases, which include seasonal allergies, year-round allergies, food allergies and asthma using various cobalamin analogues, including cyanocobalamin and methylcobalamin.

PreHistin™ is Protected by the Following US and International Patents:

US Patent #6,255,294 "Cyanocobalamin Treatment in Allergic Disease"

US Patent #5,135,918 "Method for Decreasing Reaginic Antibody Levels"

European Union Patent # EP1128835

Australian Patent #771728

Japanese Patent Pending P2002-533399A

Canadian Patent Pending 2,358,054

Mexican Patent Pending 2001-006297

Trademarks

The following are claimed trademarks of Cobalis Corp.:

PreHistin, PreHistin, Pre-Histin

PreHistamine, Pre-Histamine

The World’s First PreHistamine, The World’s First Pre-Histamine

Prevahist

Alleratin

Cobalis

Smart Science

 

 

Read SENIOR MANAGEMENT TEAM